Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
// Hung-Chih Hsu 1, 2 , Tan Kien Thiam 3 , Yen-Jung Lu 3 , Chien Yuh Yeh 2, 4 , Wen-Sy Tsai 2, 4 , Jeng Fu You 2, 4 , Hsin Yuan Hung 2, 4 , Chi-Neu Tsai 5 , An Hsu 3 , Hua-Chien Chen 3 , Shu-Jen Chen 3 , Tsai-Sheng Yang 1, 2 1 Division of Hematology-Oncology, Chang Gung Memorial Hospital, Kwei-Shan, Tao-Yuan 333, Taiwan 2 College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan 333, Taiwan 3 ACT Genomics, Neihu Dist., Taipei 114, Taiwan 4 Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Kwei-Shan, Tao-Yuan 333, Taiwan 5 Graduate Institute of Clinical Medicine, College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan 333, Taiwan Correspondence to: Shu-Jen Chen, e-mail: sjchen@actgenomics.com Tsai-Sheng Yang, e-mail: a481124@cgmh.org.tw Keywords: BRAF, metastatic colorectal cancer, RAS, mutation, cetuximab resistance Received: July 17, 2015 Accepted: February 18, 2016 Published: March 12, 2016 ABSTRACT Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers that might predict the response to cetuximab treatment. Fifty-three wild-type KRAS exon 2 mCRC patients were treated with cetuximab/irinotecan-based chemotherapy as a first- or third-line therapy. The mutational statuses of 10 EGFR pathway genes were analyzed in primary tumors using next-generation sequencing. BRAF , PIK3CA , KRAS (exons 3 and 4), NRAS , PTEN , and AKT1 mutations were detected in 6, 6, 5, 4, 1, and 1 patient, respectively. Four of the BRAF mutations were non-V600 variants. Four tumors harbored multiple co-existing (complex) mutations. All patients with BRAF mutations or complex mutation patterns were cetuximab non-responders. All patients but one harboring KRAS , NRAS , or BRAF mutations were non-responders. Mutations in any one of these three genes were associated with a poor response rate (7.1%) and reduced survival (PFS = 8.0 months) compared to wild-type patients (74.4% and 11.6 months). Our data suggest that KRAS, NRAS , and BRAF mutations predict response to cetuximab treatment in mCRC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“The detailed chemotherapy and cetuximab schedules were as follows: (i) IFL (Leucovorin 20 mg/m2 iv bolus qw x 4 weeks every 6 weeks, 5-FU 500 mg/m2 iv bolus qw x 4 weeks every 6 weeks, irinotecan 125 mg/m2 iv qw x 4 weeks every 6 weeks for 4 cycles) [42]; (ii) FOLFIRI regimen (Leucovorin 400 mg/m2 iv over 2 hours befo…”
MethodCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“In the first-line therapy group, patients with mCRC received cetuximab plus chemotherapy with FOLFIRI (irinotecan and infusional 5-fluorouracil with leucovorin) [8].”
BackgroundMethodDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 2×
“Furthermore, previous studies suggest that PIK3CA exon 20 mutations, but not PIK3CA exon 9 mutations, are associated with cetuximab resistance in CRC [22].”
BackgroundVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“also found that BRAF mutations were associated with unfavorable clinical outcomes for cetuximab- or panitumumab-based therapies [28].”
BackgroundPrenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Cited by
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
Fior, R., Póvoa, V., Mendes, R. V., Carvalho, T., Gomes, A., Figueiredo, N., & Ferreira, M. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618389114 · Cited by 320
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
“Any alterations in their components, such as KRAS, NRAS, BRAF, and PIK3CA gene mutations, can lead to constitutive activation of EGFR and the ensuing intracellular signaling and ultimately, to drug resistance [17, 18].”
BackgroundTsai, H.-L., Tai, C.-J., Huang, C.-W., Chang, F.-R., & Wang, J.-Y. (2017) · Marine Drugs · doi:10.3390/md15040122 · Cited by 156
Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells · doi:10.3390/cells12162022 · Cited by 14
“Several groups of putative response factors are discussed in the literature, including a proteomic spectra of blood serum samples [30], tumor mRNA expression biomarkers [31], transcriptome-based deduced activities of intracellular molecular pathways [32,33], EGFR expression level in tumors, and activating mutations of…”
Background
Metadata
- Authors
- Hsu, H.-C., Thiam, T. K., Lu, Y.-J., Yeh, C. Y., Tsai, W.-S., You, J. F., Hung, H. Y., Tsai, C.-N., Hsu, A., Chen, H.-C., Chen, S.-J., & Yang, T.-S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-12
- Volume
- 7
- Issue
- 16
- Pages
- 22257-22270
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2344600572
- Cited by
- 131
- References
- 13
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. https://app.cochat.ai/papers/10.18632/oncotarget.8076
- The paper
- Hsu, H.-C., Thiam, T. K., Lu, Y.-J., Yeh, C. Y., Tsai, W.-S., You, J. F., Hung, H. Y., Tsai, C.-N., Hsu, A., Chen, H.-C., Chen, S.-J., & Yang, T.-S. (2016). Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget. https://doi.org/10.18632/oncotarget.8076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.